MAP2K1 and cystic fibrosis: Furthermore, there have been no studies investigating the effects of MEK1/2 inhibitors on CF immune cells, which mount aberrant anti-microbial and inflammatory responses (Bruscia et al., 2009; Oz et al., 2022), and thus may respond differently to immune modulatory therapy as compared to cells from healthy donors.